oral PPARg phosphorylation inhibitor, partial agonist - AstraZeneca, Gothenburg, SE

oral PPARg phosphorylation inhibitor, partial agonist

efficacy in diabetic mouse model

from structure-based virtual screen

ACS Med. Chem. Lett.

AstraZeneca, Gothenburg, SE

Context. “Compound 10” (AstraZeneca) is an oral CDK5-mediated PPARγ phosphorylation inhibitor and partial PPARγ agonist being developed as an antidiabetic drug. Although widely used PPARγ agonists such as rosiglitazone…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.